Navigation Links
Atox Bio Enrolls First Patient in Phase 3 Study of Potential Treatment for Necrotizing Soft Tissue Infection (Flesh Eating Bacteria)
Date:12/7/2015

NESS ZIONA, Israel, December 7, 2015 /PRNewswire/ --

Atox Bio, developer of immunomodulatory therapeutics for rapidly-progressing infectious diseases in critically ill patients, today announced that it has enrolled the first patient in its Phase 3 study to evaluate AB103 - the first-ever candidate developed for the treatment of Necrotizing Soft Tissue Infections (NSTIs), also known as 'flesh eating bacteria'. The ACCUTE (AB103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions) study is conducted at approximately 40 centers in the U.S. and expects to enroll 290 patients who will receive around the clock coverage by highly experienced surgical teams and critical care support.

     (Logo: http://photos.prnewswire.com/prnh/20151207/293553LOGO)

NSTIs are caused by bacteria such as streptococcus, staphylococcus and others that enter the body via a minor cut, surgery, insect bite or other route and spread to the layer of connective tissue below the skin. The disease moves aggressively, causing significant destruction of tissue, and can quickly become systemic leading to multiple organ dysfunction. NSTIs are rare with 25-29,000 patients per year in the US. They are fatal in 15-20% of cases with major surgical care required for survivors. Currently, there are no approved treatments for NSTI. The standard of care includes prompt and repeated surgical debridement, resuscitation and physiologic support, in addition to antibiotics.

The previously conducted Phase 2 study demonstrated that patients treated with AB103 showed consistent and meaningful improvements. Results from the study were published in JAMA Surgery. In addition, the company has conducted a comprehensive retrospective study of NSTI that helped inform the design of the Phase 3 trial.

AB103 has received Orphan Drug status from the FDA and EMA as well as Fast Track designation. Development of AB103 is being supported by a contract with the Biomedical Advanced Research and Development Authority (BARDA).

"We are looking forward to working with the high-quality clinical sites in the ACCUTE study to evaluate AB103 in rapidly advancing NSTIs," said Dan Teleman, CEO, Atox Bio. "This is the first drug candidate designed specifically to treat this devastating disease."

Trial Design 

Patients in the Phase 3 trial will receive AB103 or placebo, administered as a single dose during or shortly after initial surgical debridement, in addition to standard of care treatment. The primary endpoint is a clinical composite based on local and systemic components of this disease. Secondary endpoints include: time to resolution of organ dysfunction, recovery from acute kidney injury and health economic outcomes such as days on ventilation, days in the ICU and duration of hospital stay.

About AB103  

AB103 is a rationally designed short peptide that modulates the patient's inflammatory response through binding to the CD28 dimer interface. It offers a unique approach in the treatment of infectious diseases by modulating the patient's own immune system and halting the uncontrolled response to pathogen detection. By targeting the host rather than the bacteria, AB103 has the potential to be effective across the spectrum of pathogen species and avoids public health issues associated with antibiotic resistance. AB103 is the first product candidate specifically developed for NSTI. Atox Bio is exploring the potential for AB103 in other critical care indications where severe acute inflammation is known to play a role in disease progression and pathogenesis.  

About Atox Bio 

Established by Prof. Raymond Kaempfer and Dr. Gila Arad from the Hebrew University of Jerusalem and Yissum, Atox Bio is a clinical stage biotechnology company that develops novel immune modulators for critically ill patients with severe infections. AB103, Atox Bio's lead product candidate, is being developed for Necrotizing Soft Tissue Infections (NSTIs) and other indications where severe acute inflammation is a central issue. The company has offices in Israel and the U.S. Investors in Atox Bio include: SR One, OrbiMed and Lundbeckfond Ventures. http://www.atoxbio.com.

Atox Bio Contact:

Dan Teleman
+972-8-648-4111
dant@atoxbio.com

For Atox Bio:

Jennifer Larson
+1-415-725-2017
jlarson@labfive.com


'/>"/>
SOURCE Atox Bio
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Celsion Corporation Enrolls First Patient in the OVATION Study
2. OrthoSpace Enrolls First Patients in US IDE Study
3. Oramed Enrolls First Patient in its Phase IIb Oral Insulin Study
4. OncoSec Medical Enrolls First Patient in Squamous Cell Carcinoma of the Head and Neck Phase II Clinical Trial
5. Oramed Enrolls First Patient in its Glucose Clamp Study for Oral Insulin
6. Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Menieres Disease
7. Epizyme Enrolls First Patient in Phase 1/2 Clinical Trial of EPZ-6438, an Inhibitor of EZH2
8. Medical ID Company Makes First Bracelet Directing EMTs To iPhone Health App
9. Amgens First Biosimilar Marketing Authorization Application Submitted To European Medicines Agency For ABP 501
10. Eisai Presents Data on Perampanel and First and Largest U.S. Study on Caregiver Burden in Epilepsy at the 69th Annual American Epilepsy Society Meeting
11. TB Alliance and Partners Announce Worlds First Availability of Appropriate, Child-friendly TB Medicines in Correct Doses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that its Board of Directors has approved the payment of ... of 2017. The cash ... about October 27, 2017 to stockholders of record as of ... of dividends are subject to approval of the Board of ...
(Date:8/4/2017)... -- Agragen, LLC, a Cincinnati -based ... and aquacultural feed sectors, announces a significant step ... AGR131.  This drug is designed to trap and ... patients suffering from inflammatory conditions such as rheumatoid ... Biological pharmaceuticals currently used ...
(Date:8/2/2017)... , Aug. 2, 2017 CaryRx, a next-generation full-service ... delivery service for patients in the Washington D.C. ... retail pharmacy by providing delivery of medications through the convenience ... future delivery or delivered within one hour to any location ... excited to bring this invaluable service to Washington ...
Breaking Medicine Technology:
(Date:8/18/2017)... CA & CARMEL, IN (PRWEB) , ... August 18, 2017 , ... ... on its 36th annual list, the most prestigious ranking of the nation's fastest-growing private ... been included in the exclusive Inc. 5000 ranking . This year’s ranking reflects ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Three Narrow Roads”: a vivid and ... of published author, Rev. Dr. Burnett King Sr., is currently the pastor-teacher-visionary at Simply ... the Faith Track Club, Inc., a track-and-field program geared towards youth. , King shares, ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Kingdom Mandate for Kingdom Builders”: ... “Kingdom Mandate for Kingdom Builders” is the creation of published author, John F. ... Eastern Europe as a missionary in 1983. He spent three decades training pastors ...
(Date:8/17/2017)... ... August 17, 2017 , ... Riccobene Associates ... location in Goldsboro, NC to its family of practices. Residents of Goldsboro will ... starting August 15, 2017. , Riccobene Associates Family Dentistry, founded by Dr. ...
(Date:8/17/2017)... MA (PRWEB) , ... August 17, 2017 , ... ... will come together on September 19, 2017 for Anti-Infectives Rx. This off-the-record networking ... B. Martin Conference Center at Harvard Medical School. , Industry leaders and decision ...
Breaking Medicine News(10 mins):